Topline phase 3 results show tasimelteon significantly advances sleep onset in adults with delayed sleep-wake phase disorder.

Type 2 diabetes is linked to regional cortical thinning and faster cognitive decline in older adults without baseline cognitive impairment.

FDA grants Priority Review to fenebrutinib NDA for RMS and PPMS based on phase 3 trial data showing significant relapse and progression reductions.

There was relatively little difference between the leading causes of death between 2023 and 2024 in the US based on national statistics.

The incidence of stroke is increasing among young adults over time, while case-fatality rates (CFRs) are decreasing, ...

Magnetic resonance imaging and positron emission tomography offer diagnostic and prognostic value in pediatric focal epilepsy.

Most patients with atypical parkinsonism and neuronal antibodies present with additional clinical features suggestive of an autoimmune etiology.

FDA approves Juvmo (tavapadon), a selective D1/D5 receptor partial agonist, for Parkinson disease based on phase 3 TEMPO trial data.

The FDA has approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis in adult and pediatric patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome).

The FDA approved Isembyld (apitegromab-mstn) for adults and pediatric patients aged 2 years and older with spinal muscular atrophy (SMA) receiving SMN2-targeted therapy.

Patients with atypical Alzheimer disease frequently fail to meet the clinical criteria required to receive targeted anti-amyloid therapies.

Pediatric patients receiving GLP-1 receptor agonist treatment appear to have higher rates of nutritional deficiency.